On Friday, Kairos Pharma Ltd (AMEX: KAPA) opened lower -5.87% from the last session, before settling in for the closing price of $0.50. Price fluctuations for KAPA have ranged from $0.40 to $4.00 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Company’s average yearly earnings per share was noted 7.25% at the time writing. With a float of $7.12 million, this company’s outstanding shares have now reached $15.83 million.
In an organization with 4 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Kairos Pharma Ltd (KAPA) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Kairos Pharma Ltd is 57.73%, while institutional ownership is 9.36%. The most recent insider transaction that took place on Nov 25 ’24, was worth 318. In this transaction VP of Research and Development of this company bought 200 shares at a rate of $1.59, taking the stock ownership to the 133,057 shares. Before that another transaction happened on Nov 22 ’24, when Company’s Chief Financial Officer bought 2,500 for $1.50, making the entire transaction worth $3,750. This insider now owns 60,796 shares in total.
Kairos Pharma Ltd (KAPA) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.05 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 7.25% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -24.45% during the next five years compared to -23.37% drop over the previous five years of trading.
Kairos Pharma Ltd (AMEX: KAPA) Trading Performance Indicators
Check out the current performance indicators for Kairos Pharma Ltd (KAPA). In the past quarter, the stock posted a quick ratio of 7.52.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.25, a number that is poised to hit -0.05 in the next quarter and is forecasted to reach -0.34 in one year’s time.
Technical Analysis of Kairos Pharma Ltd (KAPA)
Let’s dig in a bit further. During the last 5-days, its volume was 3.78 million. That was better than the volume of 1.59 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 41.13%. Additionally, its Average True Range was 0.08.
During the past 100 days, Kairos Pharma Ltd’s (KAPA) raw stochastic average was set at 4.35%, which indicates a significant decrease from 30.42% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 153.54% in the past 14 days, which was higher than the 119.63% volatility it showed in the past 100 days.
However, in the short run, Kairos Pharma Ltd’s stock first resistance to watch stands at $0.5033. Second resistance stands at $0.5335. The third major resistance level sits at $0.5595. If the price goes on to break the first support level at $0.4471, it is likely to go to the next support level at $0.4211. The third support level lies at $0.3909 if the price breaches the second support level.
Kairos Pharma Ltd (AMEX: KAPA) Key Stats
There are currently 16,849K shares outstanding in the company with a market cap of 7.97 million. Presently, the company’s annual sales total 0 K according to its annual income of -2,600 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -1,260 K.
